Brain Tumor Pathology

, 28:305 | Cite as

Grade II oligodendroglioma localized to the corpus callosum

  • Edward A. MonacoIII
  • Henry B. Armah
  • Marina N. Nikiforova
  • Ronald L. Hamilton
  • Johnathan A. Engh
Case Report


The presence of a primary central nervous system (CNS) neoplasm within the corpus callosum generally portends a grave prognosis. Common pathologies encountered include glioblastomas and primary CNS lymphomas. In contrast, World Health Organization grade II oligodendroglial tumors demonstrating loss of heterozygosity at 1p and 19q are generally less aggressive, often responding favorably to chemotherapy. The authors present a case of a primary brain tumor isolated to the corpus callosum diagnosed as a grade II oligodendroglioma. A 52-year-old woman presented with new-onset generalized seizure. Magnetic resonance imaging (MRI) revealed a non-contrast-enhancing lesion with associated edema and regional mass effect. The patient underwent a craniotomy and subtotal resection of the lesion using an endoscopic port. Pathological examination revealed a grade II oligodendroglioma. Molecular analysis identified 1p and 19q deletion as well as MGMT promoter methylation. The patient subsequently underwent adjuvant radiation therapy with an excellent response. We present, to our knowledge, the first report of a grade II oligodendroglioma isolated within the corpus callosum with the characteristic molecular features of this tumor type. Histopathologic diagnosis is essential to appropriately guide therapy of callosal tumors.


Corpus callosum Glioma Neoplasm Oligodendroglioma 


Conflict of interest



  1. 1.
    Engelhard HH (2002) Current diagnosis and treatment of oligodendroglioma. Neurosurg Focus 12:E2PubMedCrossRefGoogle Scholar
  2. 2.
    Bourekas EC, Varakis K, Bruns D, Christoforidis GA, Baujan M, Slone HW, Kehagias D (2002) Lesions of the corpus callosum: MR imaging and differential considerations in adults and pediatrics. Am J Roentgenol 179:251–257Google Scholar
  3. 3.
    Friese SA, Bitzer M, Freudenstein D, Voigt K, Kuker W (2000) Classification of acquired lesions of the corpus callosum. Neuroradiology 42:795–802PubMedCrossRefGoogle Scholar
  4. 4.
    Uchino A, Takase Y, Nomiyama K, Egashira R, Kudo S (2006) Acquired lesions of the corpus callosum: MR imaging. Eur Radiol 16:905–914PubMedCrossRefGoogle Scholar
  5. 5.
    Eichler AF, Batchelor TT (2006) Primary central nervous system lymphoma: presentation, diagnosis, and staging. Neurosurg Focus 21:E16CrossRefGoogle Scholar
  6. 6.
    Kassam AB, Engh JA, Mintz AH, Prevedello DM (2009) Completely endoscopic resection of intraparenchymal brain tumors. J Neurosurg 110:116–123PubMedCrossRefGoogle Scholar
  7. 7.
    Collins VP (2007) Mechanisms of disease: genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 4:362–374PubMedCrossRefGoogle Scholar
  8. 8.
    Quon H, Abdulkarim B (2008) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Sys Rev (2):CD007104Google Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2011

Authors and Affiliations

  • Edward A. MonacoIII
    • 1
  • Henry B. Armah
    • 3
  • Marina N. Nikiforova
    • 2
  • Ronald L. Hamilton
    • 2
  • Johnathan A. Engh
    • 1
  1. 1.Department of Neurological Surgery, UPMC PresbyterianUniversity of Pittsburgh Medical CenterPittsburghUSA
  2. 2.Department of PathologyUniversity of Pittsburgh Medical CenterPittsburghUSA
  3. 3.Harper Hospital PathologyDetroit Medical CenterDetroitUSA

Personalised recommendations